Surgical oncology

TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

Retrieved on: 
Monday, April 8, 2024
Surgeon, Plastic, Associate, Education, Matrix, National Cancer Institute, Bellevue Hospital, MD Anderson Cancer Center, NYU, University, General surgery, Surgical oncology, Health, FACS, Dentistry

MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy.

Key Points: 
  • MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy.
  • Dr. Langstein is the former Chief of Plastic and Reconstructive Surgery at the University of Rochester Medical Center, known for his extensive expertise, especially in microvascular reconstruction and innovative approaches to complex surgical problems.
  • “With more than 30 years of experience in plastic and reconstructive surgery, I understand the needs and challenges in this space,” said Dr. Langstein.
  • "We are thrilled to welcome Dr. Langstein to our team," said Paul Talmo, Chief Technology Officer of TELA Bio.

MOLLI Surgical Unveils OncoPen, a New Surgical Tool for Empowering Precision and Confidence in the Operating Room

Retrieved on: 
Tuesday, April 9, 2024
Prevalence, Patient, Cancer, Surgeon, Neoplasm, Breast cancer, Surgical oncology, Health, Birth control

DEERFIELD, Ill., April 9, 2024 /PRNewswire/ -- MOLLI Surgical continues to push the boundaries of surgical care with the launch of OncoPen™, a minimally invasive surgical tool designed to empower surgeons and improve outcomes for patients affected with breast cancer. The sleek, pen-like wand seamlessly integrates with the award-winning MOLLI® 2 System, offering sophisticated tools for precisely targeting and removing cancerous lesions.

Key Points: 
  • The sleek, pen-like wand seamlessly integrates with the award-winning MOLLI® 2 System , offering sophisticated tools for precisely targeting and removing cancerous lesions.
  • Unlike traditional techniques, it eliminates the need for wires, providing increased scheduling flexibility for surgeons and a better patient experience.
  • During surgery, the surgeon is directed using real-time 3D guidance on the MOLLI® Tablet to the precise location of the lesion.
  • "At MOLLI Surgical, our relentless focus is on the patient, placing their well-being at the core of all our efforts," said Ananth Ravi, President and CEO of MOLLI Surgical.

Research: Surgeons, Hospitals Involved in Exceptional Research Have Lower Patient Mortality Rates, Fewer Complications

Retrieved on: 
Wednesday, April 3, 2024
Software, Research, Oncology, Technology, Hospitals, Health Technology, Science, Surgery, Cardiology, Neurology, Practice Management, Health, JAMA, Evidence-based medicine, Surgeon, Urology, Environment, Physician, Impact factor, Hospital, Mortality, Patient, General surgery, Neurosurgery, Ear, Woman, Otorhinolaryngology, Male, Publication, Novant Health, Harvard Business Review, Nose, Surgical oncology, Medicare, PubMed, Elective surgery, Gastroenterology

Surgeons and hospitals who conduct the most leading-edge research achieve lower rates of patient mortality and complications than those who do not, according to findings released today by Avant-garde Health.

Key Points: 
  • Surgeons and hospitals who conduct the most leading-edge research achieve lower rates of patient mortality and complications than those who do not, according to findings released today by Avant-garde Health.
  • Patients under the care of top surgeon-researchers showed a 5% lower rate of post-discharge complications and a 5% lower rate of mortality, within 30 days post-discharge, according to the research.
  • All 4,500 physicians and 350 hospitals being honored are listed on the Research All-Stars site .
  • In addition, a significant portion of the top surgeon-researchers – 47.1% on average – served as the leading or senior authors of their research.

Lumicell Introduces Further Research and Insights in Fluorescence-Guided Surgery at the Society of Surgical Oncology (SSO) Annual Meeting

Retrieved on: 
Monday, March 25, 2024
Health, Surgery, Oncology, Medical Devices, Breast cancer, Feasibility, Detection, DVS, Massachusetts General Hospital, Light, Inc., Patient, Neoplasm, Stanford University Medical Center, NDA, University, Doctor of Philosophy, Society, Surgeon, Patient satisfaction, Surgical oncology, SSO, Hospital, PMA, Multimedia, MD Anderson Cancer Center, FDA, Associate professor, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20240325761901/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240325761901/en/
    Barbara Smith, M.D, PhD., presented results from the INSITE study during the Breast Cancer Hub Zone talk during the SSO Annual Meeting 2024.
  • “It’s so energizing to see such a diversity of surgeons across different specialties come together to advance the collective field of surgical oncology,” said Jorge Ferrer, M.D., PhD, Chief Scientific Officer, Lumicell.
  • Most recently, the FDA’s Medical Imaging Drugs Advisory Committee (MIDAC) voted in support of the benefit-risk profile of LUMISIGHT™ (pegulicianine) during its March 5, 2024 meeting .
  • The FDA is expected to make a decision on Lumicell’s NDA and PMA in the near future.

Perimeter Medical Imaging AI Provides Corporate Update on Grant Funding Opportunities and Announces Conference Call/Webcast to Discuss Fourth Quarter and Year-End 2023 Financial Results

Retrieved on: 
Wednesday, March 20, 2024
OCT, PSI, Webcast, Society, Surgeon, Clinical trial, OTC, Surgical oncology, PINK, Perimeter, DARPA, Pharmaceutical industry

DALLAS and TORONTO, March 20, 2024 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – announced upcoming events and provided a corporate update on grant funding opportunities to support its next-generation AI technology development.

Key Points: 
  • DALLAS and TORONTO, March 20, 2024 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – announced upcoming events and provided a corporate update on grant funding opportunities to support its next-generation AI technology development.
  • Although disappointing, it's important to note that these funds were proposed for future tissue type investigations and related product development.
  • We look forward to providing a more detailed corporate update when we announce our year-end 2023 results next week."
  • A telephonic playback of the conference call will be available for 14 days after the conference call by calling 1-844-512-2921 or 1-412-317-6671 and referencing conference ID 62216896.

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the F

Retrieved on: 
Tuesday, February 27, 2024
Acquisition, Breast cancer, Neoplasm, Cancer, SSO, Forecasting, MD, ASCO, Growth, GM, American College of Neuropsychopharmacology, Surgical oncology, Myriad Genetics, Society, Capital expenditure, GAAP, Genetics, American College, Health, Patient, Public expenditure, Women's health, MCRR, IPG, Video game

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its fourth quarter and full-year ended December 31, 2023 and provided its outlook on business performance for its first quarter and full-year 2024.

Key Points: 
  • GAAP operating expenses in the fourth quarter of 2023 were $166.4 million, decreasing $9.7 million year-over-year.
  • Adjusted operating expenses in the fourth quarter of 2023 decreased $8.6 million year-over-year to $130.0 million, reflecting incremental cost control measures during the fourth quarter 2023.
  • GAAP operating loss in the fourth quarter of 2023 was $31.4 million, improving $20.8 million year-over-year; adjusted operating income in the fourth quarter of 2023 was $5.7 million, improving $19.6 million year-over-year from adjusted operating loss of $13.9 million in the fourth quarter of 2022.
  • Fourth quarter 2023 GAAP cash flow from operations was $(55) million; adjusted cash flow from operations in the fourth quarter of 2023 was $14 million, an increase of $10 million year-over-year.

Lumicell Announces Initial Data Demonstrating LUMISIGHT™’s Ability to Detect Tumors Metastasized to Multiple Organs in the Peritoneum

Retrieved on: 
Tuesday, February 20, 2024
Research, Medical Devices, Surgery, Clinical Trials, Health Technology, Biotechnology, Radiology, Health, Science, Oncology, Society, Survival, Massachusetts General Hospital, Peritoneum, Hospital, Optical flow, Peritoneal cavity, Surgical oncology, Associate, Patient, Dentistry

The ongoing study is utilizing the investigational LUMISIGHT optical imaging drug and accompanying imaging device to distinguish tumor metastases to organs within the peritoneum.

Key Points: 
  • The ongoing study is utilizing the investigational LUMISIGHT optical imaging drug and accompanying imaging device to distinguish tumor metastases to organs within the peritoneum.
  • “This data advances the potential for image-guided surgery to detect small tumors and metastases to organs in the peritoneal cavity which could provide better outcomes for our patients,” said Dr. Cusack.
  • “Further innovation is desperately needed to improve the benefits of cytoreductive surgery for this invasive and elusive cancer.
  • Everything we do at Lumicell is focused on improving surgical outcomes for patients,” said Howard Hechler, President of Lumicell.

Perimeter Medical Imaging AI Announces Publication of Peer-Reviewed Research Examining the High Rates of Re-Operations Following Breast-Conserving Surgeries and the Associated Increased Healthcare Costs

Retrieved on: 
Tuesday, February 20, 2024
Woman, Perimeter, BCS, University, OTC, Surgeon, PINK, Surgical oncology, Risk, MD Anderson Cancer Center, Attention, PMID, Medicare, Mastectomy, Conversion, Patient, Research

The results of our study demonstrate that high reoperation rates after breast-conserving surgery persist and are correlated with elevated risks and adverse outcomes for patients.

Key Points: 
  • The results of our study demonstrate that high reoperation rates after breast-conserving surgery persist and are correlated with elevated risks and adverse outcomes for patients.
  • I believe that these data underscore the need for new approaches to address high reoperation rates, including better methods of margin assessment for surgeons."
  • Funding to support this research was provided, in part, by Perimeter Medical Imaging AI, Inc.
    1 Kim Y, Ganduglia-Cazaban C, Tamirisa N, Lucci A, Krause TM.
  • Contemporary Analysis of Reexcision and Conversion to Mastectomy Rates and Associated Healthcare Costs for Women Undergoing Breast-Conserving Surgery.

The Inner Circle Acknowledges, Hank C. Hill as a Pinnacle Life Member

Retrieved on: 
Monday, January 29, 2024
Surgical oncology, Philosophy, Neoplasm, Patient, Annals of Surgical Oncology, Research, Endocrine system, Sarcoma, Radiation, ABS, General surgery, Mentorship, Dance, Health, Multimedia, Knowledge, Music, Inner circle, Surgeon, National Research Service Award, Society, University, MD Anderson Cancer Center, Cancer, Skin, Gastrointestinal tract, Harlem Hospital Center, Esophagus, NIH, Liver, Stomach, Rectum, T-32, Morehouse School of Medicine, Breast, Tennis, Education, Publication, Pancreas, Endoscopy, Nursing

BROOKSVILLE, Fla., Jan. 29, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Hank C. Hill is acknowledged as a Pinnacle Life Member for his contributions to the field of Surgical Oncology.

Key Points: 
  • BROOKSVILLE, Fla., Jan. 29, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Hank C. Hill is acknowledged as a Pinnacle Life Member for his contributions to the field of Surgical Oncology.
  • Dr. Hill pursued higher education at the Brooklyn Campus of Long Island University where he earned his Bachelor of Science degree in Biology/Pre-Med.
  • Anderson Cancer Center in Houston, where he earned a surgical oncology research fellowship certificate in tumor biology.
  • Aside from his professional pursuits, Dr. Hill enjoys traveling, dancing (soca, reggae, reggaeton, R&B), and listening to music.

IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class

Retrieved on: 
Monday, January 29, 2024
Surgical oncology, Neoplasm, CentraState Medical Center, Breast imaging, SIO, DRS, Interventional radiology, Society, Breast cancer, Freezing, Oncology, Principal investigator, Education, ICE3, Radiation, Interventional oncology, Master Class, Physician, Medical imaging

This year's SIO meeting featured an educational event, Breast Cryoablation Master Class , the first of its kind by a radiology society.

Key Points: 
  • This year's SIO meeting featured an educational event, Breast Cryoablation Master Class , the first of its kind by a radiology society.
  • Interventional oncologists attending the half-day course learned from multidisciplinary experts in breast imaging, breast surgery, interventional radiology, surgical oncology, medical oncology, and radiation oncology.
  • A literature review of notable studies for breast cryoablation was presented, primarily including interim data from IceCure's ICE3 breast cancer cryoablation study, which demonstrated a 96.91% recurrence free rate.
  • Dr. Tomkovich commented, "The Master Class, which was filled to capacity, included interventional oncologists and breast radiologists seeking education to build a successful breast cryoablation program.